160 related articles for article (PubMed ID: 25401297)
41. Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring.
Crampe M; Haslam K; Kelly J; Conneally E; Langabeer SE
Hematol Oncol Stem Cell Ther; 2017 Jun; 10(2):85-88. PubMed ID: 27013275
[TBL] [Abstract][Full Text] [Related]
42. Adult acute lymphoblastic leukemia with a rare b3a3 type BCR/ABL1 fusion transcript.
Kurita D; Hatta Y; Hojo A; Kura Y; Sawada U; Kanda Y; Takei M
Cancer Genet; 2016 Apr; 209(4):161-5. PubMed ID: 26854094
[TBL] [Abstract][Full Text] [Related]
43. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Piccaluga PP; Paolini S; Martinelli G
Cancer; 2007 Sep; 110(6):1178-86. PubMed ID: 17701954
[TBL] [Abstract][Full Text] [Related]
44. Lineage switch in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Reardon DA; Hanson CA; Roth MS; Castle VP
Cancer; 1994 Mar; 73(5):1526-32. PubMed ID: 8111722
[TBL] [Abstract][Full Text] [Related]
45. A double Philadelphia chromosome-positive chronic myeloid leukemia patient, co-expressing P210
Vinhas R; Lourenço A; Santos S; Ribeiro P; Silva M; de Sousa AB; Baptista PV; Fernandes AR
Haematologica; 2018 Nov; 103(11):e549-e552. PubMed ID: 30093395
[No Abstract] [Full Text] [Related]
46. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
Drexler HG; MacLeod RA; Uphoff CC
Leuk Res; 1999 Mar; 23(3):207-15. PubMed ID: 10071072
[TBL] [Abstract][Full Text] [Related]
47. Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.
Oshikawa G; Kurosu T; Arai A; Murakami N; Miura O
Cancer Genet Cytogenet; 2010 May; 199(1):56-61. PubMed ID: 20417871
[TBL] [Abstract][Full Text] [Related]
48. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
49. Quantitative monitoring of BCR/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia.
Preuner S; Mitterbauer G; Mannhalter C; Herndlhofer S; Sperr WR; Valent P; Lion T
Eur J Cancer; 2012 Jan; 48(2):233-6. PubMed ID: 21955823
[TBL] [Abstract][Full Text] [Related]
50. Overview of clinical and genetic features of CML patients with variant Philadelphia translocations involving chromosome 7: A case series.
Bayrak AG; Daglar Aday A; Yavuz AS; Nalcaci M; Ozbalak MM; Cefle K; Ozturk S; Palanduz S
Leuk Res; 2021 Dec; 111():106725. PubMed ID: 34634595
[TBL] [Abstract][Full Text] [Related]
51. Acquired BCR-ABL1 fusion and IDH1 clonal evolution following BCL2 inhibitor treatment in refractory acute myeloid leukemia.
Adrianzen-Herrera D; Jordan-Bruno X; Devitt KA; Conant JL; Gardner JA
Leuk Res; 2021 Jan; 100():106494. PubMed ID: 33387682
[No Abstract] [Full Text] [Related]
52. A Philadelphia-negative chronic myeloid leukemia with a BCR/ABL fusion gene on chromosome 9.
Reddy KS; Grove B
Cancer Genet Cytogenet; 1998 Nov; 107(1):48-50. PubMed ID: 9809034
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2.
Ding J; Romani J; Zaborski M; MacLeod RA; Nagel S; Drexler HG; Quentmeier H
PLoS One; 2013; 8(12):e83510. PubMed ID: 24349524
[TBL] [Abstract][Full Text] [Related]
54. Induction chemotherapy and post-remission imatinib therapy for de Novo BCR-ABL-positive AML.
Lazarevic V; Golovleva I; Nygren I; Wahlin A
Am J Hematol; 2006 Jun; 81(6):470-1. PubMed ID: 16680752
[No Abstract] [Full Text] [Related]
55. The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the
Stella S; Gottardi EM; Favout V; Barragan Gonzalez E; Errichiello S; Vitale SR; Fava C; Luciano L; Stagno F; Grimaldi F; Pironi L; Sargas Simarro C; Vigneri P; Izzo B
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817063
[TBL] [Abstract][Full Text] [Related]
56. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
[TBL] [Abstract][Full Text] [Related]
57. Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia - is it all BCR-ABL?
Rumpold H; Webersinke G
Curr Cancer Drug Targets; 2011 Jan; 11(1):3-19. PubMed ID: 21062244
[TBL] [Abstract][Full Text] [Related]
58. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
Moore FR; Yang F; Press RD
Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
[TBL] [Abstract][Full Text] [Related]
59. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
Wylie AA; Schoepfer J; Jahnke W; Cowan-Jacob SW; Loo A; Furet P; Marzinzik AL; Pelle X; Donovan J; Zhu W; Buonamici S; Hassan AQ; Lombardo F; Iyer V; Palmer M; Berellini G; Dodd S; Thohan S; Bitter H; Branford S; Ross DM; Hughes TP; Petruzzelli L; Vanasse KG; Warmuth M; Hofmann F; Keen NJ; Sellers WR
Nature; 2017 Mar; 543(7647):733-737. PubMed ID: 28329763
[TBL] [Abstract][Full Text] [Related]
60. Minor BCR-ABL1-Positive Acute Myeloid Leukemia Associated With the NPM1 Mutation and FLT3 Internal Tandem Duplication.
Kim MJ; Ahn S; Jeong SH; Jang JH; Han JH; Choi JR; Cho SR
Ann Lab Med; 2016 May; 36(3):263-5. PubMed ID: 26915617
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
